Cancer Causes & Control

, Volume 23, Issue 3, pp 487–496 | Cite as

Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH–AARP Diet and Health Study Cohort

  • Louise A. Brinton
  • Lauren Schwartz
  • Margaret R. Spitz
  • Yikyung Park
  • Albert R. Hollenbeck
  • Gretchen L. Gierach
Original paper



Previous studies have reported that lung cancer risk may be decreased, increased, or unaffected by prior use of menopausal hormone therapy (MHT).


To assess this issue further, we examined relationships among 118,008 women, ages 50–71 years who were recruited during 1995–1996 for the NIH–AARP Diet and Health Study and in whom 2,097 incident lung carcinomas were identified during follow-up through 2006. Multivariable Cox proportional hazards models estimated relative risks (RR) and 95% confidence intervals (CIs) associated with various measures of self-reported MHT use.


We found no evidence that either estrogen therapy (ET)-only or estrogen plus progestin therapy (EPT) use was substantially related to subsequent lung cancer risk (respective RRs and 95% CIs for ever use = 0.97, 0.86–1.09 and 1.03, 0.90–1.17). There were no significant variations according to currency or duration of use of either formulation, nor was there evidence that risks varied within subgroups defined by cigarette smoking or body size. The absence of effect was seen for nearly all lung cancer subtypes, with the exception of an increased risk of undifferentiated/large cell cancers associated with long-term ET-only use (p trend = 0.02), a relationship not observed among EPT users.


Our results failed to support any substantial alterations in lung cancer risk associated with use of either unopposed estrogen or estrogen plus progestin MHT, even when detailed exposure measures and other risk predictors were considered.


Lung cancer Menopausal hormone therapy Risk Histology 



National Cancer Institute


American Association of Retired Persons


Menopausal hormone therapy


Relative risk


Confidence interval


Estrogen therapy


Progestin therapy


Estrogen plus progestin therapy


Non-small cell lung cancer


Not otherwise specified


Body mass index



This investigation was supported by the Intramural Research Program of the NIH.


  1. 1.
    Ramchandran K, Patel JD (2009) Sex differences in susceptibility to carcinogens. Semin Oncol 36(6):516–523PubMedCrossRefGoogle Scholar
  2. 2.
    Brinton LA, Gierach GL, Andaya A, Park Y, Schatzkin A, Hollenbeck AR, Spitz MR (2011) Reproductive and hormonal factors and lung cancer risk in the NIH–AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev 20(5):900–911PubMedCrossRefGoogle Scholar
  3. 3.
    Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, Perng RP, Huang MS, Hsiung CA, Chen CJ, Yang PC (2007) Hormone replacement therapy and lung cancer risk in Chinese. Cancer 110(8):1768–1775PubMedCrossRefGoogle Scholar
  4. 4.
    Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE (2003) Hormonal factors and risk of lung cancer among women? Int J Epidemiol 32(2):263–271PubMedCrossRefGoogle Scholar
  5. 5.
    Olsson H, Bladstrom A, Ingvar C (2003) Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 102(3):565–570PubMedCrossRefGoogle Scholar
  6. 6.
    Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, Alkhaddo J, Paganelli G, Natarajan N, Reid ME (2007) Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology 73(5–6):305–310PubMedCrossRefGoogle Scholar
  7. 7.
    Rodriguez C, Spencer FH, Deka A, Patel AV, Jacobs EJ, Thun MJ, Calle EE (2008) Postmenopausal hormone therapy and lung cancer risk in the Cancer Prevention Study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 17(3):655–660PubMedCrossRefGoogle Scholar
  8. 8.
    Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR (2004) Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10(1 Pt 1):113–123PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, Skafar DF, Lonardo F (2007) Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25(36):5785–5792PubMedCrossRefGoogle Scholar
  10. 10.
    Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ (2007) Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72(2):135–143PubMedCrossRefGoogle Scholar
  11. 11.
    Baik CS, Strauss GM, Speizer FE, Feskanich D (2010) Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses’ Health Study. Cancer Epidemiol Biomarkers Prev 19(10):2525–2533PubMedCrossRefGoogle Scholar
  12. 12.
    Blackman JA, Coogan PF, Rosenberg L, Strom BL, Zauber AG, Palmer JR, Langenberg P, Shapiro S (2002) Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11(7):561–567PubMedCrossRefGoogle Scholar
  13. 13.
    Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O’Sullivan MJ et al (2010) Lung cancer among postmenopausal women treated with estrogen alone in the Women’s Health Initiative randomized trial. J Natl Cancer Inst 102(18):1413–1421PubMedCrossRefGoogle Scholar
  14. 14.
    Elliott AM, Hannaford PC (2006) Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Contraception 73(4):331–335PubMedCrossRefGoogle Scholar
  15. 15.
    Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC et al (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post hoc analysis of a randomised controlled trial. Lancet 374(9697):1243–1251PubMedCrossRefGoogle Scholar
  16. 16.
    Kabat GC, Miller AB, Rohan TE (2007) Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 120(10):2214–2220PubMedCrossRefGoogle Scholar
  17. 17.
    Slatore CG, Chien JW, Au DH, Satia JA, White E (2010) Lung cancer and hormone replacement therapy: association in the Vitamins and Lifestyle Study. J Clin Oncol 28(9):1540–1546PubMedCrossRefGoogle Scholar
  18. 18.
    Smith JR, Barrett-Connor E, Kritz-Silverstein D, Wingard DL, Al-Delaimy WK (2009) Hormone use and lung cancer incidence: the Rancho Bernardo Cohort Study. Menopause 16(5):1044–1048PubMedCrossRefGoogle Scholar
  19. 19.
    Liu Y, Inoue M, Sobue T, Tsugane S (2005) Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 117(4):662–666PubMedCrossRefGoogle Scholar
  20. 20.
    Taioli E, Wynder EL (1994) Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86(11):869–870PubMedCrossRefGoogle Scholar
  21. 21.
    Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, Freedman LS, Brown CC et al (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154(12):1119–1125PubMedCrossRefGoogle Scholar
  22. 22.
    Michaud DS, Micthune D, Hermansen S et al (2005) Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Regist Manag 32:70–75Google Scholar
  23. 23.
    Fritz A, Percy C, Jack A, et al. (2000) International classification of diseases for oncology, 3 Geneva, SwitzerlandGoogle Scholar
  24. 24.
    Gail NH, Lubin JH, Rubinstein LV (1981) Likelihood calculations for matched case-control studies and survival studies with tied death times. Biometrika 68:703–707CrossRefGoogle Scholar
  25. 25.
    Grimes DA, Schulz KF (2005) Compared to what? Finding controls for case-control studies. Lancet 365(9468):1429–1433PubMedCrossRefGoogle Scholar
  26. 26.
    Clague J, Reynolds P, Sullivan-Halley J, Ma H, Lacey JV Jr, Henderson KD, Ursin G, West DW, Chang S, Delclos G, Du XL, Forman MR, et al. (2011) Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. Cancer Epidemiol Biomarkers Prev 20(3):560–564Google Scholar
  27. 27.
    Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L (1989) Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44(5):833–839PubMedCrossRefGoogle Scholar
  28. 28.
    Kabat GC, Kim M, Hunt JR, Chlebowski RT, Rohan TE (2008) Body mass index and waist circumference in relation to lung cancer risk in the Women’s Health Initiative. Am J Epidemiol 168(2):158–169PubMedCrossRefGoogle Scholar
  29. 29.
    Smith L, Brinton LA, Spitz MR, Lam TK, Park Y, Hollenbeck AR, Freedman ND, Gierach GL (2011) Body mass index and lung cancer risk among never, former, and current smokers. J Natl Cancer Inst (in press)Google Scholar
  30. 30.
    Oh SW, Myung SK, Park JY, Lym YL, Ju W (2010) Hormone therapy and risk of lung cancer: a meta-analysis. J Womens Health (Larchmt) 19(2):279–288CrossRefGoogle Scholar
  31. 31.
    Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, Horvath S, Chia D, Garon E, Goodglick L, Pietras RJ (2011) Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids 76(9):910–920PubMedGoogle Scholar
  32. 32.
    Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K, Kaaks R, Trichopoulou A et al (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105(5):709–722PubMedCrossRefGoogle Scholar
  33. 33.
    Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC (2008) Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 9(7):649–656PubMedCrossRefGoogle Scholar
  34. 34.
    Siegfried JM, Hershberger PA, Stabile LP (2009) Estrogen receptor signaling in lung cancer. Semin Oncol 36(6):524–531PubMedCrossRefGoogle Scholar
  35. 35.
    Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551PubMedCrossRefGoogle Scholar
  36. 36.
    Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150–3160PubMedCrossRefGoogle Scholar
  37. 37.
    Koushik A, Parent ME, Siemiatycki J (2009) Characteristics of menstruation and pregnancy and the risk of lung cancer in women. Int J Cancer 125(10):2428–2433PubMedCrossRefGoogle Scholar
  38. 38.
    Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113(5):1027–1037PubMedGoogle Scholar
  39. 39.
    Weiss JM, Lacey JV Jr, Shu XO, Ji BT, Hou L, Yang G, Li H, Rothman N, Blair A, Gao YT, Chow WH, Zheng W (2008) Menstrual and reproductive factors in association with lung cancer in female lifetime nonsmokers. Am J Epidemiol 168(11):1319–1325PubMedCrossRefGoogle Scholar
  40. 40.
    Zatloukal P, Kubik A, Pauk N, Tomasek L, Petruzelka L (2003) Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer 41(3):283–293PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. (outside the USA) 2012

Authors and Affiliations

  • Louise A. Brinton
    • 1
  • Lauren Schwartz
    • 2
  • Margaret R. Spitz
    • 3
  • Yikyung Park
    • 4
  • Albert R. Hollenbeck
    • 5
  • Gretchen L. Gierach
    • 6
  1. 1.Division of Cancer Epidemiology and Genetics, National Cancer InstituteNational Institutes of HealthRockvilleUSA
  2. 2.Division of Cancer Epidemiology and Genetics, National Cancer InstituteNational Institutes of HealthRockvilleUSA
  3. 3.Dan L. Duncan Cancer CenterBaylor College of MedicineHoustonUSA
  4. 4.Division of Cancer Epidemiology and Genetics, National Cancer InstituteNational Institutes of HealthRockvilleUSA
  5. 5.Organizational and Tracking Research DepartmentAARPWashingtonUSA
  6. 6.Division of Cancer Epidemiology and Genetics, National Cancer InstituteNational Institutes of HealthRockvilleUSA

Personalised recommendations